Pharmacologic and functional characterization of malignant hyperthermia in the R163C RyR1 knock-in mouse. - Wikidata - wikimedia - TriplyDB

Pharmacologic and functional characterization of malignant hyperthermia in the R163C RyR1 knock-in mouse.

Pharmacologic and functional characterization of malignant hyperthermia in the R163C RyR1 knock-in mouse.

http://www.wikidata.org/entity/Q34583987

about

Malignant hyperthermia PharmGKB summary: succinylcholine pathway, pharmacokinetics/pharmacodynamics Malignant hyperthermia: a review Ca(V)1.1: The atypical prototypical voltage-gated Ca²⁺ channel Divergent Activity Profiles of Type 1 Ryanodine Receptor Channels Carrying Malignant Hyperthermia and Central Core Disease Mutations in the Amino-Terminal Region Anesthetic- and heat-induced sudden death in calsequestrin-1-knockout mice Myoplasmic resting Ca2+ regulation by ryanodine receptors is under the control of a novel Ca2+-binding region of the receptor.RyR1-mediated Ca2+ leak and Ca2+ entry determine resting intracellular Ca2+ in skeletal myotubes.Ca2+ influx via the Na+/Ca2+ exchanger is enhanced in malignant hyperthermia skeletal muscle.A malignant hyperthermia-inducing mutation in RYR1 (R163C): alterations in Ca2+ entry, release, and retrograde signaling to the DHPR.A malignant hyperthermia-inducing mutation in RYR1 (R163C): consequent alterations in the functional properties of DHPR channels Dantrolene mitigates caerulein-induced pancreatitis in vivo in mice.Malignant hyperthermia susceptibility arising from altered resting coupling between the skeletal muscle L-type Ca2+ channel and the type 1 ryanodine receptor Muscle weakness in Ryr1I4895T/WT knock-in mice as a result of reduced ryanodine receptor Ca2+ ion permeation and release from the sarcoplasmic reticulum.Basal bioenergetic abnormalities in skeletal muscle from ryanodine receptor malignant hyperthermia-susceptible R163C knock-in mice.Functional and biochemical properties of ryanodine receptor type 1 channels from heterozygous R163C malignant hyperthermia-susceptible mice.Malignant hyperthermia: a pharmacogenetic disorder.Accelerated activation of SOCE current in myotubes from two mouse models of anesthetic- and heat-induced sudden death.Gene dose influences cellular and calcium channel dysregulation in heterozygous and homozygous T4826I-RYR1 malignant hyperthermia-susceptible muscle.Mice expressing T4826I-RYR1 are viable but exhibit sex- and genotype-dependent susceptibility to malignant hyperthermia and muscle damage Antioxidants protect calsequestrin-1 knockout mice from halothane- and heat-induced sudden death.Nonspecific sarcolemmal cation channels are critical for the pathogenesis of malignant hyperthermia.Halothane modulation of skeletal muscle ryanodine receptors: dependence on Ca2+, Mg2+, and ATP.Genetically manipulated mice: a powerful tool with unsuspected caveats.Enhanced excitation-coupled calcium entry in myotubes expressing malignant hyperthermia mutation R163C is attenuated by dantrolene.Ca2+ dysregulation in Ryr1(I4895T/wt) mice causes congenital myopathy with progressive formation of minicores, cores, and nemaline rods Calsequestrin-1: a new candidate gene for malignant hyperthermia and exertional/environmental heat stroke.Ryanodine receptor studies using genetically engineered mice.The disorders of the calcium release unit of skeletal muscles: what have we learned from mouse models?A guide to the 3D structure of the ryanodine receptor type 1 by cryoEM.Genotype-Phenotype Correlations of Malignant Hyperthermia and Central Core Disease Mutations in the Central Region of the RYR1 Channel.Altered Ca2+ homeostasis in the skeletal muscle of DJ-1 null mice.Ryanodine receptor type 1 (RyR1) possessing malignant hyperthermia mutation R615C exhibits heightened sensitivity to dysregulation by non-coplanar 2,2',3,5',6-pentachlorobiphenyl (PCB 95).Successful management of malignant hyperpyrexia syndrome in a pediatric patient: What to do when dantrolene is not available?Estrogens Protect Calsequestrin-1 Knockout Mice from Lethal Hyperthermic Episodes by Reducing Oxidative Stress in Muscle.Altered Ca2+ concentration, permeability and buffering in the myofibre Ca2+ store of a mouse model of malignant hyperthermia.Voltage modulates halothane-triggered Ca2+ release in malignant hyperthermia-susceptible muscle.Malignant Hyperthermia in the Post-Genomics Era: New Perspectives on an Old Concept.Strenuous exercise triggers a life-threatening response in mice susceptible to malignant hyperthermia.Reduced threshold for store overload-induced Ca2+ release is a common defect of RyR1 mutations associated with malignant hyperthermia and central core disease.

P2860

Q21203008-7A1C865E-5989-440B-B776-CB8E23D965E8 Q26781824-34ABDDA3-197A-4828-9567-06DE62119806 Q26799652-2F9E243E-131E-4AC6-9801-8C06CA96F022 Q26866428-F0D41074-FB61-4FE3-A79F-EB9434FAA13E Q28118185-5626D76D-9CE3-43AB-AA73-ACB52A3C5624 Q28511309-E6163A2E-6868-4297-99AA-AF30983E6A94 Q33606502-321458EA-AD35-405D-982B-839D7D67AD31 Q33810099-91EFE0FE-00A8-46F3-8BE3-650C6EE42D1D Q33846552-F3C720E3-3467-4FEA-976C-B69555369B5D Q33922807-E84C6294-2E02-49B4-AD26-54BB6C3E8331 Q33922848-D801855E-5B9A-4179-9B4C-3C275EA57EEE Q33994773-BE4411B2-FA4D-4AFD-B4DE-811DC778A458 Q34252541-AD779801-2998-4356-9CE7-DA7037404798 Q34439584-2672F182-083B-4E0D-B8CD-042C2BE17B22 Q34452842-4E9760D8-6F48-41A1-936A-C3FAB9B01044 Q34701056-0C5BB130-BFCF-47F2-B3D9-D9A74953E471 Q34883560-F775F457-9589-4E41-9D75-94341E107A14 Q35021801-F8E7E9ED-6A4B-46D3-9DE0-AA44A6235648 Q35704843-5052D6DB-6D87-4F64-8341-3B3F28E4B9CB Q35787753-51708871-ACCD-4E59-990F-D99797987A63 Q35977425-C6413693-B2D0-4FC7-BE1A-6BD35E2E35DC Q36615166-629FC5DE-A4CF-4DBC-99FD-7DB0485795A5 Q36768338-57552200-CE8B-4BBF-AC2F-78837ACB5EB1 Q36818129-9F7968BB-A40C-4B88-95DC-8480C283B359 Q37328327-17D61EBB-F98B-4AFA-88C0-1CA39582F3BA Q37458493-9B6FBAD7-0B7B-4965-BC68-A9F06E273A8F Q37471099-D1466C0E-B3E4-40ED-BF3D-16B34E3D15E3 Q37705608-9EE03612-7F83-46FF-872F-7C889992936B Q38271367-8311722C-8915-4A13-8733-4C69F1F80566 Q38964992-BDED766D-B21C-4B24-BDB7-831EE40AC2BC Q39430392-7C504642-820C-4D33-B207-C4EF11E5D7C4 Q41221578-B58F88BF-EE16-4CA0-B059-02DB48763AB2 Q42108975-60B66654-7145-47CD-BA01-8BF53AB8E2EC Q43086602-DC626765-E176-4CDE-B751-D2F4D3FD2288 Q43118514-5451E19B-6EC5-4780-A365-199FC3CBD01D Q44411113-7A76F7F2-A2A7-4693-B18A-DB8214E0F972 Q47220248-64A82072-D86D-4138-B464-98E4EA1A76F9 Q47253099-A633C543-193E-41CC-8715-082C7B993E86 Q47300757-8C40FC59-4305-47FC-B7FD-2516E80B8FC0 Q49577286-54241B4F-2C8B-49A1-AD15-EDD0C611832E

P2860

Pharmacologic and functional characterization of malignant hyperthermia in the R163C RyR1 knock-in mouse.

http://www.wikidata.org/entity/Q34583987

description

2006 nî lūn-bûn

@nan

2006 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Pharmacologic and functional c ...... the R163C RyR1 knock-in mouse.

@ast

Pharmacologic and functional c ...... the R163C RyR1 knock-in mouse.

@en

Pharmacologic and functional c ...... the R163C RyR1 knock-in mouse.

@nl

type

label

Pharmacologic and functional c ...... the R163C RyR1 knock-in mouse.

@ast

Pharmacologic and functional c ...... the R163C RyR1 knock-in mouse.

@en

Pharmacologic and functional c ...... the R163C RyR1 knock-in mouse.

@nl

prefLabel

Pharmacologic and functional c ...... the R163C RyR1 knock-in mouse.

@ast

Pharmacologic and functional c ...... the R163C RyR1 knock-in mouse.

@en

Pharmacologic and functional c ...... the R163C RyR1 knock-in mouse.

@nl

P1433

Q34583987-A4F9332D-4486-439C-9C03-0FD17F981D5A

P1476

Q34583987-C7518D21-A949-42A7-87F4-999F391039B5

P2093

Q34583987-1703DAF5-86D8-4803-918D-0F1F8E545553

Q34583987-6974E109-7E26-46FF-8552-8DEECB3420B4

Q34583987-9EE9F940-7D57-41C3-B86B-EBD83ECD3F3D

Q34583987-A3DD3EAD-FD20-4CF6-9EB6-B173C61EC7B5

Q34583987-A6822A10-3D00-443D-9BA7-BE4FA16CAFF4

Q34583987-AAD37546-3B1E-407D-976A-196FE853C5B9

Q34583987-B72F2B43-923B-4FA4-9D0F-CEAF0E2C4D74

Q34583987-BA007B6C-A9B5-4D85-86A2-4245402BD853

P304

Q34583987-FE0CC60A-0F9E-4C0D-8B61-FCA76BFCC8FB

P31

Q34583987-26E6DA2A-9015-4537-A54A-2BBBC066490B

P356

Q34583987-B0CE53AB-0911-475C-B720-2B4530B8CC5B

P407

Q34583987-D4000565-DF3C-4965-BB01-D6455E9B7F31

P433

Q34583987-5BE0B6D1-05F1-42AD-9F72-466519A5BEC7

P478

Q34583987-8CD7B9A3-DF31-4B96-BB09-BB051C06C1D5

P577

Q34583987-16F409F4-66DB-49F8-8090-9284C7700EED

P5875

Q34583987-399EC72B-EAF7-49AC-8C8F-C9CE12AFE383

P698

Q34583987-1E5DF992-FD57-4BBD-BBB5-389B2D68BEEB

P921

Q34583987-3694F803-8958-4D46-8D4E-77A2F04BA30A

P356

00000542-200612000-00016

P1433

P1476

Pharmacologic and functional c ...... the R163C RyR1 knock-in mouse.

@en

P2093

Eric Esteve

http://www.w3.org/2001/XMLSchema#string

Isaac N Pessah

http://www.w3.org/2001/XMLSchema#string

José R Lopez

http://www.w3.org/2001/XMLSchema#string

Joyce Riehl

http://www.w3.org/2001/XMLSchema#string

Klaus I Matthaei

http://www.w3.org/2001/XMLSchema#string

Paul D Allen

http://www.w3.org/2001/XMLSchema#string

Samuel Goth

http://www.w3.org/2001/XMLSchema#string

Tianzhong Yang

http://www.w3.org/2001/XMLSchema#string

P304

1164-1175

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/00000542-200612000-00016

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

105

http://www.w3.org/2001/XMLSchema#string

P577

2006-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

232211585

http://www.w3.org/2001/XMLSchema#string

P698

17122579

http://www.w3.org/2001/XMLSchema#string

P921